Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

被引：103

作者：

Russell-Jones, David ^{[1
]}

机构：

[1] Royal Surrey Cty Hosp, Dept Endocrinol & Diabet, Guildford GU2 7XX, Surrey, England

来源：

MOLECULAR AND CELLULAR ENDOCRINOLOGY | 2009年 / 297卷 / 1-2期

关键词：

GLP-1; analogue; Hypoglycaemia; Body weight; Systolic blood pressure; GLUCAGON-LIKE PEPTIDE-1; GLYCEMIC CONTROL; GENE-EXPRESSION; BETA-CELLS; DERIVATIVES; WEIGHT; SULFONYLUREA; NN2211;

D O I：

10.1016/j.mce.2008.11.018

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical Studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA(1c), low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：137 / 140

页数：4

共 50 条

[21] Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
Horowitz, Michael
Flint, Anne
Jones, Karen L.
Hindsberger, Charlotte
Rasmussen, Mads F.
Kapitza, Christoph
Doran, Selena
Jax, Thomas
Zdravkovic, Milan
Chapman, Ian M.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2012, 97 (02) : 258 - 266
[22] Pharmacokinetic modelling of the once-daily human GLP-1 analogue liragiutide in healthy volunteers and comparison to exenatide
Jonker, Daniel
Toft, Anders D.
Kristensen, Peter
Knudsen, Lotte
Watson, Estelle
DIABETES, 2007, 56 : A160 - A160
[23] The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials
Plutzky, J.
Garber, A. J.
Falahati, A.
Toft, A. D.
Poulter, N. R.
EUROPEAN HEART JOURNAL, 2009, 30 : 917 - 917
[24] Once-Daily Human GLP-1 Analog Liraglutide Reduces Systolic BP-A Meta-Analysis of 6 Clinical Trials
Fonseca, Vivian
Madsbad, Sten
Falahati, Ali
Zychma, Marcin J.
Plutzky, Jorge
DIABETES, 2009, 58 : A146 - A146
[25] Greater glycaemic control is achieved with the once-daily human GLP-1 analogue liraglutide vs comparators across the continuum of estimated beta cell mass
Meier, J. J.
Vilsboll, T.
Donsmark, M.
Hartvig, H.
Nauck, M. A.
DIABETOLOGIA, 2011, 54 : S322 - S322
[26] Liraglutide, the once-daily human GLP-1 analogue, has a protracted profile based on both delayed absoprtion and a long plasma half-life
Knudsen, L. Bjerre
Nielsen, P. F.
Steensgaard, D. B.
Bloch, P.
Lau, J.
Agersoe, H.
DIABETOLOGIA, 2009, 52 : S305 - S306
[27] Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
Horowitz, M.
Vilsboll, T.
Zdravkovic, M.
Hammer, M.
Madsbad, S.
DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 593 - U4
[28] Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subject and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase
Bjornsdottir, I.
Olsen, A.
Larsen, U.
Helleberg, H.
Vanggaard, J.
Oosterhuis, B.
van Lier, J.
Zdravkovic, M.
Malm-Erjefalt, M.
DIABETOLOGIA, 2008, 51 : S356 - S356
[29] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
Astrup, A.
Carraro, R.
Finer, N.
Harper, A.
Kunesova, M.
Lean, M. E. J.
Niskanen, L.
Rasmussen, M. F.
Rissanen, A.
Rossner, S.
Savolainen, M. J.
Van Gaal, L.
INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) : 843 - 854
[30] Liraglutide, a once-daily human GLP-1 analog, significantly improves β-cell function in subjects with type 2 diabetes
Matthews, David
Marre, Michel
Le-Thl, T. U. Duyen
Zdravkovic, Milan
Simo, Rafael
DIABETES, 2008, 57 : A150 - A151

← 1 2 3 4 5 →